Rule 3.19A.3

# **Appendix 3Z**

### **Final Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Creso Pharma Limited	
ABN	89 609 406 911	

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	James Ellingford
Date of last notice	8 November 2021
Date that director ceased to be director	30 November 2022

#### Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part

# Number & class of securities 1,152,500 Fully Paid Ordinary Shares 384,167 CPHO Options (\$0.25, 2 Nov 2024)

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest	Number & class of securities
Note: Provide details of the circumstances giving rise to	
the relevant interest	

11/3/2002 Appendix 3Z Page 1

<sup>+</sup> See chapter 19 for defined terms.

## Part 3 – Director's interests in contracts

N/A

Appendix 3Z Page 2 11/3/2002

<sup>+</sup> See chapter 19 for defined terms.